tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Allarity Therapeutics Completes Additional Private Equity Financing

Story Highlights
  • Allarity completed a private placement begun September 22, 2025, raising $2.5 million.
  • An additional closing on December 23, 2025 raised $250,000 for working capital needs.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Allarity Therapeutics Completes Additional Private Equity Financing

Claim 70% Off TipRanks This Holiday Season

Allarity Therapeutics ( (ALLR) ) has provided an update.

On September 22, 2025, Allarity Therapeutics entered into a securities purchase agreement with an accredited investor for a private placement of 1,562,500 shares of common stock and/or pre-funded warrants, raising approximately $2.5 million in gross proceeds, and on December 23, 2025, the company completed an additional closing under that agreement. At this additional closing, Allarity sold a further 255,103 common shares at $0.98 per share, the minimum price permitted under Nasdaq rules, generating about $250,000 in gross proceeds that it plans to use for general corporate purposes and working capital, with the unregistered securities issued under a private placement exemption and subject to restrictive legends, highlighting the company’s continued reliance on exempt equity financings to support its operations.

The most recent analyst rating on (ALLR) stock is a Buy with a $9.25 price target. To see the full list of analyst forecasts on Allarity Therapeutics stock, see the ALLR Stock Forecast page.

Spark’s Take on ALLR Stock

According to Spark, TipRanks’ AI Analyst, ALLR is a Underperform.

Allarity Therapeutics’ overall stock score is low due to significant financial challenges, including no revenue and consistent operational losses. Technical analysis shows a bearish trend with neutral momentum indicators, while valuation metrics are unfavorable with a negative P/E ratio and no dividend yield. These factors collectively suggest a high-risk investment with limited current appeal.

To see Spark’s full report on ALLR stock, click here.

More about Allarity Therapeutics

Allarity Therapeutics, Inc. is a biotechnology company focused on developing cancer therapies, operating within the life sciences and pharmaceutical industry and funded in part through capital markets transactions such as private placements of its common stock.

Average Trading Volume: 246,703

Technical Sentiment Signal: Sell

Current Market Cap: $16.28M

For an in-depth examination of ALLR stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1